Pharmaceuticals, Biotechnology and Life Sciences
Stoke Therapeutics is on track to begin enrollment and dosing of STK-001 in Part A of Phase 1/2a “Monarch” clinical trial in children and adolescents with Dravet syndrome in 2H 2020.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its initial public offering of 9,074,776 shares of its common stock at a price to the public of $18.00 per share, which includes 1,183,666 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. today announced the appointment of Stephen J. Tulipano, CPA, MBA as chief financial officer. Mr.…